Cellceutix Receives Notice of Acceptance for Phase 1 Clinical Trial
News Jul 20, 2011
Cellceutix Corporation reports that it has received notice of acceptance for a clinical trial of Kevetrin™, Cellceutix's flagship compound as an indication for drug-resistant cancers, to be conducted at one of the world's most prominent cancer centers.
"I am pleased to announce this significant milestone in the development of Kevetrin," commented Leo Ehrlich, CEO of Cellceutix.
Ehrlich continued, "Our research to date on Kevetrin™ has been stellar and the approval to conduct our clinical trials at what many believe to be the world's foremost cancer research center adds a great deal of validation to our beliefs that Kevetrin™ could be one of the leading cancer compounds known at this time. Additional details will be coming upon finalization of review and signed contracts."
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE